This injectable medication marked the beginning of a new therapeutic class for type 2 diabetes and weight management
A study from the Employee Benefit Research Institute (EBRI), supported by the Blue Cross Blue Shield Association and other partners, estimates that GLP-1 coverage would be a major premium driver for employer-provided coverage
For retatrutide specifically, the Phase 2 trial was too short and too small to draw meaningful conclusions about cancer risk
Effekten konsekvent oavsett lder Samtidigt understryker studien att medicinernas effekt r konsekvent och likvrdig oavsett patientens lder, etniska bakgrund eller ursprungliga kroppsmasseindex
In daily practice, substantial cost savings to the healthcare system are possible if biological-naive patients are initially treated with biosimilars, or if patients who already receive the reference biological DMARDs (bDMARDs) are switched to the corresponding biosimilar product [94]
Coupling endoplasmic reticulum stress to the cell death program